Literature DB >> 20919954

Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression.

Yanlin Jiang1, Shaoyu Zhou, George E Sandusky, Mark R Kelley, Melissa L Fishel.   

Abstract

Pancreatic cancer is a deadly disease that is virtually never cured. Understanding the chemoresistance intrinsic to this cancer will aid in developing new regimens. High expression of APE1/Ref-1, a DNA repair and redox signaling protein, is associated with resistance, poor outcome, and angiogenesis; little is known in pancreatic cancer. Immunostaining of adenocarcinoma shows greater APE1/Ref-1 expression than in normal pancreas tissue. A decrease in APE1/Ref-1 protein levels results in pancreatic cancer cell growth inhibition, increased apoptosis, and altered cell cycle progression. Endogenous cell cycle inhibitors increase when APE1/ Ref-1 is reduced, demonstrating its importance to proliferation and growth of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20919954      PMCID: PMC2966714          DOI: 10.3109/07357907.2010.512816

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  47 in total

1.  TSH controls Ref-1 nuclear translocation in thyroid cells.

Authors:  G Tell; L Pellizzari; C Pucillo; F Puglisi; D Cesselli; M R Kelley; C Di Loreto; G Damante
Journal:  J Mol Endocrinol       Date:  2000-06       Impact factor: 5.098

2.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.

Authors:  Claus Storgaard Sørensen; Randi G Syljuåsen; Jacob Falck; Tine Schroeder; Lars Rönnstrand; Kum Kum Khanna; Bin-Bing Zhou; Jiri Bartek; Jiri Lukas
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

3.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

Authors:  C E Arris; F T Boyle; A H Calvert; N J Curtin; J A Endicott; E F Garman; A E Gibson; B T Golding; S Grant; R J Griffin; P Jewsbury; L N Johnson; A M Lawrie; D R Newell; M E Noble; E A Sausville; R Schultz; W Yu
Journal:  J Med Chem       Date:  2000-07-27       Impact factor: 7.446

4.  Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.

Authors:  Meraj Mohiuddin; Damodaran Chendil; Swatee Dey; Rachael A Alcock; William Regine; Mohammed Mohiuddin; Mansoor M Ahmed
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

Review 5.  Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.

Authors:  Lili Liu; Stanton L Gerson
Journal:  Curr Opin Investig Drugs       Date:  2004-06

6.  Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.

Authors:  Jeremy P H Chow; Wai Yi Siu; Horace T B Ho; Ken Hoi Tang Ma; Chui Chui Ho; Randy Y C Poon
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

7.  Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A.

Authors:  Zusen Fan; Paul J Beresford; Dong Zhang; Zhan Xu; Carl D Novina; Akira Yoshida; Yves Pommier; Judy Lieberman
Journal:  Nat Immunol       Date:  2003-01-13       Impact factor: 25.606

8.  Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition.

Authors:  Dong Wang; Meihua Luo; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2004-06       Impact factor: 6.261

Review 9.  Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.

Authors:  John P Duffy; Guido Eibl; Howard A Reber; Oscar J Hines
Journal:  Mol Cancer       Date:  2003-01-22       Impact factor: 27.401

10.  Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.

Authors:  J P Lau; K L Weatherdon; V Skalski; D W Hedley
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more
  33 in total

1.  Characterization of the redox activity and disulfide bond formation in apurinic/apyrimidinic endonuclease.

Authors:  Meihua Luo; Jun Zhang; Hongzhen He; Dian Su; Qiujia Chen; Michael L Gross; Mark R Kelley; Millie M Georgiadis
Journal:  Biochemistry       Date:  2012-01-04       Impact factor: 3.162

2.  Redox regulation of apurinic/apyrimidinic endonuclease 1 activity in Long-Evans Cinnamon rats during spontaneous hepatitis.

Authors:  Soumendra Krishna Karmahapatra; Tapas Saha; Sanjay Adhikari; Jordan Woodrick; Rabindra Roy
Journal:  Mol Cell Biochem       Date:  2013-12-15       Impact factor: 3.396

3.  Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.

Authors:  Melissa L Fishel; Yanlin Jiang; N V Rajeshkumar; Glenda Scandura; Anthony L Sinn; Ying He; Changyu Shen; David R Jones; Karen E Pollok; Mircea Ivan; Anirban Maitra; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2011-06-23       Impact factor: 6.261

4.  Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages.

Authors:  Andrej Jedinak; Shailesh Dudhgaonkar; Mark R Kelley; Daniel Sliva
Journal:  Anticancer Res       Date:  2011-02       Impact factor: 2.480

5.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

6.  Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Mark R Kelley; James H Wikel; Chunlu Guo; Karen E Pollok; Barbara J Bailey; Randy Wireman; Melissa L Fishel; Michael R Vasko
Journal:  J Pharmacol Exp Ther       Date:  2016-09-08       Impact factor: 4.030

7.  Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.

Authors:  Derek P Logsdon; Michelle Grimard; Meihua Luo; Safi Shahda; Yanlin Jiang; Yan Tong; Zhangsheng Yu; Nicholas Zyromski; Ernestina Schipani; Fabrizio Carta; Claudiu T Supuran; Murray Korc; Mircea Ivan; Mark R Kelley; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

8.  Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer.

Authors:  Melissa L Fishel; Hanyu Xia; Jack McGeown; David W McIlwain; May Elbanna; Ariel A Craft; Hristos Z Kaimakliotis; George E Sandusky; Chi Zhang; Roberto Pili; Mark R Kelley; Travis J Jerde
Journal:  Mol Cancer Ther       Date:  2019-08-14       Impact factor: 6.261

9.  Apurinic/apyrimidinic endonuclease-1 is associated with angiogenesis and VEGF production via upregulation of COX-2 expression in esophageal cancer tissues.

Authors:  Hiroyuki Nagoya; Seiji Futagami; Mayumi Shimpuku; Atsushi Tatsuguchi; Taiga Wakabayashi; Hiroshi Yamawaki; Yasuhiro Kodaka; Tetsuro Kawagoe; Yasuhiko Watarai; Hiroshi Makino; Masao Miyashita; Shinichi Tsuchiya; Sheila E Crowe; Choitsu Sakamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

10.  Apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1) redox function negatively regulates NRF2.

Authors:  Melissa L Fishel; Xue Wu; Cecilia M Devlin; Derek P Logsdon; Yanlin Jiang; Meihua Luo; Ying He; Zhangsheng Yu; Yan Tong; Kelsey P Lipking; Anirban Maitra; N V Rajeshkumar; Glenda Scandura; Mark R Kelley; Mircea Ivan
Journal:  J Biol Chem       Date:  2014-12-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.